Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in treatment and prevention of recurrence of anogenital warts (HIPvac trial)

Macey L Murray; Jade Meadows; Caroline J. Dore; Andrew Copas; Lewis J. Haddow; Charles John Nash Lacey; M. Jit; Kate Soldan; Kate Bennett; Michelle Tetlow; Mayura Nathan; Richard Gilson

Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in treatment and prevention of recurrence of anogenital warts (HIPvac trial)

Macey L Murray, Jade Meadows, Caroline J. Dore, Andrew Copas, Lewis J. Haddow, Charles John Nash Lacey, M. Jit, Kate Soldan, Kate Bennett, Michelle Tetlow, Mayura Nathan, Richard Gilson

The Hull York Medical School

Research output: Contribution to journal › Article › peer-review

Original language	English
Number of pages	9
Journal	BMC Medical Research Methodology
Volume	18
Issue number	125
Publication status	Published - 6 Nov 2018

Bibliographical note

Access to Document

s12874-018-0581-z
© The Author(s). 2018
Final published version, 626 KBLicence: CC BY

Cite this

Murray, M. L., Meadows, J., Dore, C. J., Copas, A., Haddow, L. J., Lacey, C. J. N., Jit, M., Soldan, K., Bennett, K., Tetlow, M., Nathan, M., & Gilson, R. (2018). Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in treatment and prevention of recurrence of anogenital warts (HIPvac trial). BMC Medical Research Methodology, 18(125).

Murray, Macey L ; Meadows, Jade ; Dore, Caroline J. et al. / Human papillomavirus infection : protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in treatment and prevention of recurrence of anogenital warts (HIPvac trial). In: BMC Medical Research Methodology. 2018 ; Vol. 18, No. 125.

@article{e06c20a7f80e4a65a60d45613569f570,

title = "Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in treatment and prevention of recurrence of anogenital warts (HIPvac trial)",

author = "Murray, {Macey L} and Jade Meadows and Dore, {Caroline J.} and Andrew Copas and Haddow, {Lewis J.} and Lacey, {Charles John Nash} and M. Jit and Kate Soldan and Kate Bennett and Michelle Tetlow and Mayura Nathan and Richard Gilson",

note = "{\textcopyright} The Author(s). 2018.",

year = "2018",

month = nov,

day = "6",

language = "English",

volume = "18",

journal = "BMC Medical Research Methodology",

issn = "1471-2288",

publisher = "BioMed Central",

number = "125",

}

Murray, ML, Meadows, J, Dore, CJ, Copas, A, Haddow, LJ, Lacey, CJN, Jit, M, Soldan, K, Bennett, K, Tetlow, M, Nathan, M & Gilson, R 2018, 'Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in treatment and prevention of recurrence of anogenital warts (HIPvac trial)', BMC Medical Research Methodology, vol. 18, no. 125.

Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in treatment and prevention of recurrence of anogenital warts (HIPvac trial). / Murray, Macey L; Meadows, Jade; Dore, Caroline J. et al.
In: BMC Medical Research Methodology, Vol. 18, No. 125, 06.11.2018.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Human papillomavirus infection

T2 - protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in treatment and prevention of recurrence of anogenital warts (HIPvac trial)

AU - Murray, Macey L

AU - Meadows, Jade

AU - Dore, Caroline J.

AU - Copas, Andrew

AU - Haddow, Lewis J.

AU - Lacey, Charles John Nash

AU - Jit, M.

AU - Soldan, Kate

AU - Bennett, Kate

AU - Tetlow, Michelle

AU - Nathan, Mayura

AU - Gilson, Richard

PY - 2018/11/6

Y1 - 2018/11/6

M3 - Article

SN - 1471-2288

VL - 18

JO - BMC Medical Research Methodology

JF - BMC Medical Research Methodology

IS - 125

ER -

Murray ML, Meadows J, Dore CJ, Copas A, Haddow LJ, Lacey CJN et al. Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in treatment and prevention of recurrence of anogenital warts (HIPvac trial). BMC Medical Research Methodology. 2018 Nov 6;18(125).